Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures (Natalie Breymeyer/Axios)

Mithrl, an AI infrastructure company for biopharma, has successfully raised $20 million in a Series A funding round. This investment was led by Obvious Ventures, as confirmed by CEO Vivek Adarsh. Mithrl specializes in integrating its proprietary biomedical world model directly with the R&D systems of pharmaceutical companies, aiming to enhance their research and development capabilities.